Emerging phagocytosis checkpoints in cancer immunotherapy

Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as it utilizes patients' own immune systems in combating the cancer cells. Cancer cells escape immune surveillance by hijacking the corresponding inhibitory pathways via overexpressing checkpoint genes. Phagocytosis checkpoints, such as CD47, CD24, MHC-I, PD-L1, STC-1 and GD2, have emerged as essential checkpoints for cancer immunotherapy by functioning as "don't eat me" signals or interacting with "eat me" signals to suppress immune responses. Phagocytosis checkpoints link innate immunity and adaptive immunity in cancer immunotherapy.…

• NN
  National Natural Science Foundation of China

  Awards: 82122056, 31830053, 8207112072, 31920103007, 31830053, 31920103007
• NN
  National Natural Science Foundation of China-Yunnan Joint Fund

  Awards: 31830053, 19QA1406700, 82073274
• NK
  National Key Research and Development Program of China

  Award: 2020YFA0803201